Explain in detail disseminated intravascular coagulation (DIC), thrombotic thrombocytopenic purpura (TTP), and sepsis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 16, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Disseminated Intravascular Coagulation (DIC)

DIC is an acquired, life-threatening syndrome characterized by systemic intravascular coagulation activation with loss of localization, endothelial injury, and impaired fibrinolysis that can cause microvascular damage leading to organ dysfunction, with mortality rates reaching 24.8% in septic patients. 1, 2

Pathophysiology

DIC is not a disease itself but a pathomechanistic process accompanying various underlying conditions 1. The condition involves three critical components:

  • Systemic coagulation activation: Widespread activation of the clotting cascade throughout the vasculature
  • Endothelial injury: Essential component per ISTH definition, though current diagnostic criteria paradoxically don't include endothelial biomarkers 1
  • Impaired anticoagulation and persistent fibrinolysis suppression: Leading to microvascular thrombosis 3

The pathogenesis follows an innate immune-based coagulation model with four phases: initiation, amplification, propagation, and reinforcement 3. Key drivers include:

  • Histones from cellular damage acting as damage-associated molecular patterns (DAMPs)
  • Crosstalk between hypoxic inflammation and coagulation
  • Serine protease network dysregulation (coagulation, fibrinolysis, kallikrein-kinin system, complement pathways) 3

The degree of endothelial dysfunction varies significantly by underlying cause: highly significant in sepsis-induced coagulopathy, moderate in trauma-induced coagulopathy, and variable in hematologic malignancy-associated DIC 1.

Clinical Presentation

DIC manifests in two distinct phenotypes 4:

Thrombotic DIC:

  • Microvascular thrombosis predominates
  • Multiple organ dysfunction syndrome
  • Ischemic organ damage

Hemorrhagic DIC:

  • Consumption coagulopathy
  • Oozing and difficult-to-control bleeding
  • Depletion of coagulation factors and platelets

Diagnostic Approach

Phase-Based Classification (2025 ISTH Update)

The 2025 ISTH framework introduces three phases 4:

  1. Pre-DIC: Preclinical laboratory abnormalities
  2. Early-phase DIC (compensated/subclinical): Laboratory abnormalities preceding clinical symptoms
  3. Overt DIC: Advanced stage with clear coagulopathy and organ failure

ISTH Overt DIC Scoring System (Updated 2025)

A mandatory prerequisite is the presence of an underlying disorder known to be associated with DIC 2, 5.

Scoring criteria 4:

  • Platelet count:

    • <50 × 10⁹/L = 2 points
    • ≥50 to <100 × 10⁹/L = 1 point
  • D-dimer (revised 2025 thresholds):

    • 7× upper normal limit = 3 points

    • 3× upper normal limit = 2 points

  • Prothrombin time (PT-INR):

    • ≥6 seconds prolongation = 2 points
    • ≥3 to <6 seconds = 1 point
  • Fibrinogen:

    • <1.0 g/L = 1 point

Score ≥5 = Overt DIC 5

Sepsis-Induced Coagulopathy (SIC) Score

For early detection in septic patients, use the SIC score first, then progress to overt DIC criteria if positive 6, 5. This two-step approach is the recommended pragmatic diagnostic strategy 6.

SIC Scoring 5:

  • Platelet count:

    • <100 × 10⁹/L = 2 points
    • ≥100 to <150 × 10⁹/L = 1 point
  • PT-INR:

    • 1.4 = 2 points

    • 1.2 to ≤1.4 = 1 point

  • SOFA score (respiratory + cardiovascular + hepatic + renal):

    • ≥2 = 2 points
    • 1 = 1 point

Score ≥4 = SIC (compensated DIC) 5

SIC predicts development of overt DIC with high sensitivity and has mortality ≥30% 6. It enables earlier therapeutic intervention before decompensation occurs 6.

Laboratory Findings

Characteristic patterns 2:

  • Decreased coagulation factors (including fibrinogen)
  • Thrombocytopenia
  • Increased fibrin degradation products
  • Prolonged PT and aPTT beyond what dilution alone would cause 7

Endothelial markers (not in standard criteria but clinically useful) 1:

  • Antithrombin activity (decreased)
  • von Willebrand factor (elevated)

Critical Pitfall: Distinguishing DIC from TTP

DIC and thrombotic thrombocytopenic purpura (TTP) can appear similar but require completely different management 8, 9. Use the TTP/DIC index:

TTP/DIC Index = FXIII activity (%) ÷ haptoglobin (mg/dL) 8

  • Index ≥60 = TTP (sensitivity 94.3%, specificity 86.7%)
  • Index <60 = DIC

Key distinguishing features 8, 9:

  • TTP: Severe haptoglobin depletion (<2.868 mg/dL), preserved FXIII (>76%), microangiopathic hemolytic anemia, markedly decreased ADAMTS13 activity
  • DIC: Preserved haptoglobin, decreased FXIII (<76%), hyperfibrinolysis, activation of all coagulation systems

Management

Primary Treatment

Treating the underlying condition is absolutely crucial and takes priority over all other interventions 7, 3.

Supportive Therapies

Component replacement 7:

  • Fresh frozen plasma (FFP): Consider after one blood volume lost; dose must be large enough to maintain factors above critical levels
  • Cryoprecipitate: When fibrinogen remains <1.0 g/L despite FFP
  • Platelets: For thrombocytopenia with bleeding or high bleeding risk
  • Timing: Give sooner rather than later in sufficient dosage, avoiding circulatory overload 7

Anticoagulant Therapy

Japanese Clinical Practice Guidelines 2024 and ISTH recommend antithrombin or recombinant thrombomodulin for sepsis-associated DIC 10.

Evidence considerations 6, 11:

  • Meta-analyses show trend toward better outcomes in patients with septic DIC (not just sepsis alone)
  • Antithrombin: Greatest benefit in patients with DIC and antithrombin activity ≤43% 6
  • Recombinant thrombomodulin: Post-hoc analyses suggest benefit in patients with higher baseline thrombin markers 6
  • Selection of optimal target patients is critical for effectiveness

Antifibrinolytic Therapy

Tranexamic acid: Recommended only in trauma-induced coagulopathy within limited initial timing window 12. Do not use routinely in septic DIC where fibrinolysis suppression already predominates 11.

High-Risk Situations Requiring Aggressive Monitoring

Patients at particular risk for DIC development 7:

  • Prolonged hypoxia or hypovolemia
  • Cerebral or extensive muscle damage
  • Hypothermia after cold resuscitation fluid infusion

Monitor frequently: Platelet count, fibrinogen, PT, aPTT; consider FDP or D-dimers 7. Prolongation of PT/aPTT beyond dilution expectations, plus thrombocytopenia and fibrinogen <1.0 g/L are highly suggestive of DIC 7.


Thrombotic Thrombocytopenic Purpura (TTP)

TTP is a life-threatening thrombotic microangiopathy requiring immediate plasma exchange, corticosteroids, and caplacizumab upon clinical suspicion, with mortality reduced from 15.7% to 3.9% by plasma exchange and further to 2.2% with comprehensive treatment including rituximab. 13

Epidemiology and Definition

Global incidence of immune-mediated TTP (iTTP): 1-6 cases per million people per year 13. TTP is characterized by platelet-consuming microvascular thrombi but differs fundamentally from DIC in pathophysiology 8, 9.

Pathophysiology

TTP results from severe ADAMTS13 deficiency 13:

  • Immune-mediated TTP (iTTP): Autoantibodies against ADAMTS13
  • Congenital TTP (cTTP): Genetic mutations affecting ADAMTS13

Unlike DIC where all coagulation, fibrinolysis, and platelet systems activate, TTP involves marked platelet activation only 9. The absence of widespread coagulation activation explains preserved coagulation factors.

Clinical Presentation

Classic pentad (not always present):

  • Thrombocytopenia
  • Microangiopathic hemolytic anemia (MAHA)
  • Neurological symptoms
  • Renal dysfunction
  • Fever

Microangiopathic hemolytic anemia is observed in most TTP patients 9, distinguishing it from DIC.

Diagnostic Approach

ADAMTS13 activity measurement is the diagnostic gold standard 13.

Laboratory Findings Distinguishing TTP from DIC

TTP-specific findings 8, 9:

  • Haptoglobin: Severely depleted (median 0.39 mg/dL; cutoff <2.868 mg/dL)
  • FXIII activity: Preserved (median 91.3%; cutoff >76%)
  • ADAMTS13 activity: Markedly decreased
  • Coagulation tests: PT and aPTT typically normal (unlike DIC)
  • Fibrinogen: Normal or elevated (unlike DIC where it's consumed)

DIC-specific findings 8:

  • Haptoglobin: Relatively preserved (median 54.20 mg/dL)
  • FXIII activity: Decreased (median 36.3%; cutoff <76%)
  • Hyperfibrinolysis: Present in most cases 9
  • Coagulation tests: Prolonged PT/aPTT

TTP/DIC Index for Rapid Differentiation

Formula: FXIII activity (%) ÷ haptoglobin (mg/dL) 8

  • ≥60 = Laboratory TTP (sensitivity 94.3%, specificity 86.7%)
  • <60 = Laboratory DIC

This index provides rapid differentiation when both conditions are in the differential, which is critical because treatments differ completely.

Management

Acute Treatment (Initiate Immediately on Clinical Suspicion)

Do not wait for ADAMTS13 results to begin treatment 13.

Standard acute therapy 13:

  1. Plasma exchange: Reduces mortality from 15.7% to 3.9%
  2. Corticosteroids: Part of standard regimen
  3. Caplacizumab: Anti-von Willebrand factor nanobody
  4. Rituximab: Added to standard treatment

Comprehensive treatment (plasma exchange + corticosteroids + caplacizumab + rituximab) achieves 2.2% mortality versus 12.2% in historical controls 13.

Follow-Up Management

Long-term monitoring is essential 13:

  • Regular clinical follow-up
  • ADAMTS13 activity monitoring
  • Detection and treatment of late sequelae
  • Pregnancy management: Requires monitoring and recurrence prophylaxis in female TTP patients

Critical Pitfall: Sepsis-Induced DIC with TTP Features

Rare cases of septic DIC can present with low ADAMTS13 activity and positive ADAMTS13 inhibitor, mimicking iTTP 14. These represent a specific fulminant syndrome with fatal outcomes. When sepsis is clearly present with DIC features but ADAMTS13 is low, treat the underlying infection aggressively while considering plasma exchange.


Sepsis

Sepsis is defined as life-threatening organ dysfunction caused by dysregulated host responses to infection, with the prothrombotic/antithrombotic balance shifted toward prothrombotic states that can progress to sepsis-induced coagulopathy (SIC) and disseminated intravascular coagulation. 10

Pathophysiology

Coagulation in Sepsis

The prothrombotic shift in sepsis is initially a physiological defense mechanism 10:

  • Intended to contain infection in peripheral tissues
  • Prevents spread to central systems
  • When response fails to remain localized → extensive ischemic organ damage → sepsis-associated DIC with multiple organ failure

Key Pathogenic Mechanisms

Endothelial dysfunction is highly significant in sepsis-induced coagulopathy 1:

  • Endotoxin absorption: From intestines into systemic circulation → sustained inflammation → platelet and coagulation activation 2
  • Endothelial activation: Expresses adhesion molecules, facilitating microthrombus formation 1
  • Glycocalyx damage: Disrupts cellular interactions in thromboinflammation 1
  • Tissue factor release: Triggers coagulation activation

Fibrinolysis suppression 5, 11:

  • Overproduction of plasminogen activator inhibitor-1 (PAI-1)
  • Hallmark of sepsis-associated DIC (unlike malignancy-associated DIC)
  • Creates prothrombotic effects with potential for organ dysfunction

Progression Model

Sepsis → Sepsis-Induced Coagulopathy (SIC) → Overt DIC 6, 5

This represents a continuum from compensated to decompensated coagulation disorder.

Clinical Presentation and Organ Dysfunction

Sepsis-induced coagulopathy frequently complicates the early phase with multiorgan dysfunction 5. Unlike trauma-induced coagulopathy, SIC lacks an initial hemorrhagic phase 12.

Organ dysfunction patterns:

  • Respiratory failure
  • Cardiovascular collapse
  • Hepatic dysfunction
  • Renal failure
  • Neurological impairment

Diagnostic Approach

Sequential Organ Failure Assessment (SOFA) Score

SOFA score is essential for sepsis definition and SIC diagnosis 5. Components:

  • Respiratory SOFA
  • Cardiovascular SOFA
  • Hepatic SOFA
  • Renal SOFA

Two-Step Diagnostic Algorithm for Coagulopathy in Sepsis

Step 1: Screen with SIC Score 6, 5

SIC Criteria (requires sepsis diagnosis):

  • Platelet count: <100 × 10⁹/L (2 points) or ≥100 to <150 × 10⁹/L (1 point)
  • PT-INR: >1.4 (2 points) or >1.2 to ≤1.4 (1 point)
  • SOFA score: ≥2 (2 points) or 1 (1 point)

Score ≥4 = SIC (compensated DIC)

SIC characteristics 6:

  • Predicts development of overt DIC with high sensitivity
  • Mortality ≥30%
  • Enables earlier therapeutic intervention
  • All tests are inexpensive and routine in ICU

Step 2: Progress to Overt DIC Criteria if SIC Positive 6, 5

Use ISTH overt DIC scoring (see DIC section above). Score ≥5 = Overt DIC.

Biomarkers for Severity Assessment

Endothelium-related markers (not in standard criteria but useful) 1:

  • Antithrombin activity: Decreased; reflects severity
  • von Willebrand factor: Elevated; reflects endothelial injury

Thrombin-related markers 6:

  • Prothrombin fragment 1.2
  • Thrombin-antithrombin complex
  • Higher baseline levels identify patients with greater benefit from anticoagulation

Management

Primary Treatment

Treat the underlying infection aggressively 11, 3, 10. This is the most critical intervention and takes absolute priority.

Supportive Care

Hemostatic resuscitation and circulatory support are essential 12:

  • Fluid resuscitation
  • Vasopressor support
  • Mechanical ventilation as needed
  • Renal replacement therapy for acute kidney injury

Anticoagulant Therapy in Sepsis-Associated DIC

Japanese Clinical Practice Guidelines for Management of Sepsis and Septic Shock 2024 recommend antithrombin or recombinant thrombomodulin for sepsis-associated DIC 10.

Evidence base 6, 11:

  • Large randomized trials of anticoagulants in severe sepsis (without DIC specification) failed to show benefit
  • Meta-analyses in septic DIC patients show trend toward better outcomes
  • Patient selection is critical for optimizing anticoagulant use

Antithrombin 6:

  • Greatest mortality reduction in patients with DIC and antithrombin activity ≤43%
  • Consider measuring antithrombin activity to identify optimal candidates

Recombinant thrombomodulin 6:

  • Post-hoc analyses suggest greater benefit in patients with higher baseline prothrombin fragment 1.2 or thrombin-antithrombin complex
  • Consider measuring thrombin-related markers to identify suitable subjects

Substitution Therapies

Component replacement (see DIC section):

  • Fresh frozen plasma
  • Cryoprecipitate (if fibrinogen <1.0 g/L)
  • Platelets

What NOT to Do

Do not use antifibrinolytics routinely in septic DIC 11, 12. Fibrinolysis is already suppressed in sepsis-induced coagulopathy due to PAI-1 overproduction. Tranexamic acid is only indicated in trauma-induced coagulopathy within a limited time window.

Monitoring Strategy

Frequent laboratory monitoring 7:

  • Platelet count
  • PT/aPTT
  • Fibrinogen
  • D-dimer or FDP
  • SOFA score components

Repeat SIC and overt DIC scoring to track progression and response to treatment 6.

Prognosis

Mortality rates 1:

  • Septic patients with DIC: 24.8%
  • Early detection with SIC criteria enables intervention before decompensation
  • Comprehensive treatment including appropriate anticoagulation in selected patients may improve outcomes

References

Research

Disseminated intravascular coagulation.

Journal of intensive care, 2025

Guideline

management of massive blood loss: a template guideline.

British Journal of Anaesthesia, 2000

Research

[Disseminated intravascular coagulation associated with sepsis].

[Rinsho ketsueki] The Japanese journal of clinical hematology, 2025

Research

Sepsis-Induced Coagulopathy and Disseminated Intravascular Coagulation.

Seminars in thrombosis and hemostasis, 2020

Research

Sepsis-induced disseminated intravascular coagulation with features of thrombotic thrombocytopenic purpura: a fatal fulminant syndrome.

Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis, 2011

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.